Background: In endemic COVID-19, immunocompromised children are vulnerable until vaccinated but the optimal primary vaccination regime and need for booster doses remains uncertain.
Methods: We recruited 19 immunocompromised children (post-solid organ transplantation, have autoimmune disease or were on current or recent chemotherapy for acute lymphoblastic leukemia), and followed them from the start of primary vaccination with BNT162b2 mRNA SARS-CoV-2 until 1-year post-vaccination. We investigated the quality of vaccine immunogenicity, and longevity of hybrid immunity, in comparison to healthy children.
Australas J Dermatol
December 2024
Phaeohyphomycosis has been described to cause a variety of cutaneous manifestations in both immunocompetent and immunocompromised hosts. We report an unexpected case where an immunocompetent elderly female developed a rare angioinvasive fungal cutaneous infection. She had no known history of inoculation, and her lesions resolved without treatment.
View Article and Find Full Text PDFBackground: Immunoresistance to botulinum neurotoxin A (BoNT-A) due to neutralizing antibodies (NAbs) can lead to partial or complete secondary nonresponse (SNR), potentially limiting individuals' aesthetic and/or medical therapeutic options in the short and/or long term. Understanding factors directly or indirectly influencing BoNT-A immunoresistance risk is crucial.
Aims: This analysis explored patterns of latent risk factors (biological and behavioral) that may influence the risk of developing BoNT-A immunoresistance among experienced aesthetic BoNT-A recipients.